ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2019
Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Unveiling the efficacy predictors and potential mechanisms ofFrontiers in immunology · 2026Pooled it
- Cuscuta chinensis Lam. extract alleviates ovariectomy-induced osteoporosis by inhibiting VCP-mediated METTL3 protein degradation.Journal of molecular histology · 2026Article
- Flavonoids ofPreventive nutrition and food science · 2026Article
- Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.Chinese medicine · 2026Review
- 90-Day Subchronic Toxicological Evaluation of a Zylaria in Sprague Dawley Rats.Journal of toxicology · 2026Article
- Mechanistic Potentials of Natural Herbal Medicines (NHMs) in Promoting Bone Regeneration: A Comprehensive Review.Current drug metabolism · 2026Review
- RANK hypomethylation is associated with primary osteoporosis in elderly men in Xinjiang: a case-control study.BMC medical genomics · 2025Article
- 7-Hydroxyflavone Mitigates OsteoporosisCurrent topics in medicinal chemistry · 2025Article
- Antiresorptive effect of a semisynthetic triterpene from Combretum leprosum Mart. on dexamethasone-induced osteoporosis in rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Therapeutic roles and molecular mechanisms of Cuscutae Semen in reproductive diseases.Frontiers in immunology · 2025Review
- Exploring the Wound Healing Potential of aPharmaceutics · 2024Article
- Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats.Molecules (Basel, Switzerland) · 2024Article
- Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity.Frontiers in pharmacology · 2024Review
- Osteogenic mechanism of chlorogenic acid and its application in clinical practice.Frontiers in pharmacology · 2024Review
- The Role of Herbal Medicine in Modulating Bone Homeostasis.Current topics in medicinal chemistry · 2024Review
- Pharmacological importance of Kunxian Capsule in clinical applications and its adverse effects: A review.Chinese herbal medicines · 2023Review
- Glucocorticoid-induced osteoporosis is prevented by dietary prune in female mice.Frontiers in cell and developmental biology · 2023Article
- Identification of a Hydroxygallic Acid Derivative, Zingibroside R1 and a Sterol Lipid as Potential Active Ingredients ofNutrients · 2022Article
- Antiosteoporosis and bone protective effect of dieckol against glucocorticoid-induced osteoporosis in rats.Frontiers in endocrinology · 2022Article
- Aucubin slows the development of osteoporosis by inhibiting osteoclast differentiation via the nuclear factor erythroid 2-related factor 2-mediated antioxidation pathway.Pharmaceutical biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuscuta chinensis Lam. (Convolvulaceae) is an important herbal medicine widely used to improve sexual function, treat osteoporosis, and prevent aging, and has been reported to exhibit anti-osteoporotic effects in vitro. However, the activity of Cuscuta chinensis Lam. on glucocorticoid-induced osteoporosis still remains unclear. The present study aimed to assess the protective effect and the underlying mechanism of action of Cuscuta chinensis extract (CCE) against glucocorticoid-induced osteoporosis in vivo. Sprague-Dawley rats were randomly divided into four groups as follows: control group, osteoporosis group, and 2 CCE-treated osteoporosis groups (100 mg·kg-1·day-1). Blood samples and femur bones were collected for immunohistochemistry, biochemical, mRNA expression, and western blot analysis. HPLC analysis revealed that chlorogenic acid, quercetin, and hyperin were the major constituents of CCE. The results indicated that CCE increased bone length, bone weight, and bone mineral density and suppressed dexamethasone (DEX)-induced reduction in body weight. In addition, TRAP staining indicated that CCE reduced osteoclasts in DEX-induced osteoporosis rats. Mechanistically, CCE treatment alleviated the increase of bone resorption markers and the decline of osteogenic markers, which might be partially mediated by regulation of RANKL/OPG and RunX2 pathways. These results suggest that CCE showed promising effects in the protection against glucocorticoid-induced osteoporosis through protecting osteoblasts and suppressing osteoclastogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.